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1Charité Universitaetsmedizin Berlin, Institute of Physiology, Structural Bioinformatics Group, Berlin 10117, Germany
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ABSTRACT
The development of new drugs for diseases is a
time-consuming, costly and risky process. In recent
years, many drugs could be approved for other in-
dications. This repurposing process allows to ef-
fectively reduce development costs, time and, ul-
timately, save patients’ lives. During the ongoing
COVID-19 pandemic, drug repositioning has gained
widespread attention as a fast opportunity to find
potential treatments against the newly emerging dis-
ease. In order to expand this field to researchers
with varying levels of experience, we made an ef-
fort to open it to all users (meaning novices as well
as experts in cheminformatics) by significantly im-
proving the entry-level user experience. The brows-
ing functionality can be used as a global entry
point to collect further information with regards to
small molecules (∼1 million), side-effects (∼110 000)
or drug-target interactions (∼3 million). The drug-
repositioning tab for small molecules will also sug-
gest possible drug-repositioning opportunities to the
user by using structural similarity measurements for
small molecules using two different approaches. Ad-
ditionally, using information from the Promiscuous
2.0 Database, lists of candidate drugs for given indi-
cations were precomputed, including a section ded-
icated to potential treatments for COVID-19. All the
information is interconnected by a dynamic network-
based visualization to identify new indications for
available compounds. Promiscuous 2.0 is unique
in its functionality and is publicly available at http:
//bioinformatics.charite.de/promiscuous2.
INTRODUCTION
The promiscuity of small molecule compounds and proteins
can be described as their ability to bind to a number of tar-
gets and, specifically, in the case of drugs, to different tar-
gets in addition to the intended main target (1). Since the
modulation of off-target activity can lead to unintended
and potentially harmful side-effects, promiscuity was of-
ten regarded as a negative trait (2,3). However, following
the increased availability of compound-target interaction
data, an increased number of formerly unknown promis-
cuous interactions and proteins became known, and the
term polypharmacology was coined for multitarget bind-
ing activity (4,5). Since the development of drugs is an ex-
pensive process which can cost up to two billion US dollar
(6,7), pharmaceutical companies quickly became interested
in exploiting drug promiscuity as a means to cut develop-
ment and approval costs of new drugs by reassigning al-
ready approved drugs to different application areas derived
from their off-targets (8–10). Due to the increased interest
in using drug-target relations to reposition drugs for new in-
dications, a number of databases were developed in recent
years with a focus on providing information and features
useful for this purpose. Regarding the ongoing COVID-19
pandemic, drug repositioning is an especially promising ap-
proach in order to find treatments or cures, since in addition
to cutting development costs, it also significantly decreases
the time for approval, which is of great importance during
the rapid spread of a new disease (11–13).
In recent years, several different approaches, both bio-
logical and computational, were used to find new areas
of application for already approved drugs. Experimental
approaches include target screening approaches, cell as-
say approaches, animal model approaches and clinical ap-
proaches, whereas computational approaches are, for in-
stance structure-, network- or text-mining-based (14). A va-
riety of biological databases such as Drugbank (15) and
ChEMBL (16) exist, which can provide the information
which is necessary to build a potential drug repositioning
pipeline.
Unfortunately, the scope of existing databases that focus
directly on drug repurposing is limited, as they either serve
as a pure compilation of successfully repositioned drugs
(17,18) or completely lack interactive features (19,20). Most
importantly, there is currently no database that provides
possible indications for a compound of interest in an eas-
ily accessible way or shows data in a visual and interactive
fashion. With Promiscuous 2.0, we aim to close this gap by
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providing a powerful yet easy to use resource, which enables
experts and non-experts alike to create complex interaction
networks in an intuitive and interactive way, and potentially
infer new indications for existing compounds. Moreover, it
is possible to search for existing drugs or even submit new
molecular structures and be presented with suggested appli-
cation areas or, vice versa, get potential drug candidates for
disease indications of interest; a completely unique feature
across all published databases, which was also tested and
applied in order to create a list of candidate drugs against
COVID-19.
MATERIALS AND METHODS
Architecture of Promiscuous 2.0
Promiscous was designed as a comprehensive database of
information to identify potential drug repositioning oppor-
tunities. For this, an extensive integration of available data
is necessary. To ensure high data quality, different quality
control and filter steps were included.
In comparison to the first version of Promiscuous, the
number of drugs and drug-like compounds was vastly in-
creased from formerly 25,000 to almost a million.
Drug-target information was included from DrugBank
(15), ChEMBL (16), SuperDrug2 (21), Supertarget (22) and
combined into this comprehensive database. To only con-
sider highly accurate and direct interactions between small
molecules and proteins, which are necessary to provide vi-
able drug repositioning strategies, the data was filtered and
standardized.
Afterwards a variety of information was compiled to fur-
ther enrich the data, most of which is neither included in the
old Promiscuous database nor in comparable resources.
Information regarding side effect occurrence and fre-
quency for the extracted drugs was obtained from the
SIDER resource (v. 4.1) (23), which does not only contain
adverse events occurring during the clinical trials phase but
also those identified post-approval.
Newly included in Promiscuous 2.0 are predicted targets
for a total of almost 600 000 drugs and small molecule com-
pounds which were inferred using the SuperPred Webserver
(24) as well as disease indications for both drugs and targets.
Those were obtained in the form of ICD-10 codes from the
Therapeutic Target Database (25).
Technical background
The entirety of the data contained in Promiscuous 2.0 is
stored in a relational MySQL database and hosted on the
Charité IT system. Backend functionality is provided via
a lab-based LAMP (Linux/Apache/MySQL/PHP) server.
PHP serves as the backend language, connecting to the
database through the MySQL interface and delivering data
to the frontend via a mixture of classic html form submis-
sion responses and AJAX requests.
As the website functionalities rely strongly on JavaScript
and its plugin jQuery (https://jquery.com/) the usage of a
JavaScript capable browser is essential and, due to more ex-
tensive testing, Google Chrome is recommended. Various
functionality from the CSS-Framework Bootstrap https:
//getbootstrap.com/) is used on the website. Additionally,
tables were created using the jQuery plugin-in DataTa-
bles (https://datatables.net), along with its absolute sorting
extension (https://datatables.net/plug-ins/sorting/absolute).
Charts on the website were created with the JavaScript li-
brary amCharts 4 (https://www.amcharts.com/), the net-
work uses the Javascript library D3.js (https://d3js.org/).
The machine learning was implemented in Python using
a random forest approach provided by the Python pack-
age, scikit-learn (https://scikit-learn.org/stable/). In order
to assess molecular features, molecule structures were con-
verted to MACCS molecular fingerprints (26) using RDKit
(https://www.rdkit.org/) and, based on the indication map-
ping provided by the TTD database (25), used as input in
order to predict the effectiveness of given molecular struc-
tures against disease indications.
USER INTERFACE
The main aim of Promiscuous 2.0 is to provide a freely avail-
able, powerful and easily accessible resource for drug reposi-
tioning opportunities. By providing different searching lev-
els, non-experts as well as experts can work with this re-
source. The interactive network visualization provides easy
access for all users to complex drug-target and target/drug
to indication interplay.
Drug repositioning
The major new feature in Promiscuous 2.0 provides the
unique opportunity to search for drugs and compounds
with the goal of obtaining potential areas of interest for
drug repositioning, as well as suggest drugs and molecu-
lar structures from the Promiscuous 2.0 database for indica-
tions of interest. Therefore, there are two options to explore
potential drug repositioning opportunities: Starting with a
molecular structure, possible areas of application are pro-
vided and starting from an indication of interest, potentially
applicable drugs are reported.
When exploring drug repositioning opportunities for a
molecular structure in question, the input compound is de-
fined by the user providing its molecular structure (Figure
1E), either from PubChem via entering its PubChem name,
by providing a SMILES string or MOLFile/ChemDoodle
JSON, or by drawing the structure. As a result, the drug
repositioning option is not only viable for known and ap-
proved drugs, but also for experimental compounds which
are not included in the Promiscuous 2.0 database at the time
of the search. In order to provide a comprehensive result,
two different approaches are implemented, based on ma-
chine learning and overall structural similarity to known
drugs.
In order to use a machine learning approach for the pre-
diction of possible areas of application, indications were
grouped according to their ICD-10 3-letter categories, due
to the requirement of a suitable number of known drugs to
build a viable prediction model. Upon entering a molecu-
lar structure of interest, it is compared to each of the pre-
calculated models. As a result, the tool lists each indication
group for which the corresponding model reported a prob-
ability of at least 80% of being associated with the struc-
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Figure 1. Schema showing the different resources (A) used to create Promiscuous 2.0 and a collection of features such as predicted targets (B), the results
of the drug repositioning option (C), an example network (D) and the integrated drug search options (E).
scored like unknown entries on the result screen, allowing
for a point of comparison for newly reported categories.
The detection of potential drug repositioning areas for
a given molecular structure according to structural sim-
ilarity is based on the assumption that structural sim-
ilarity leads to similar interaction profiles. Therefore, a
similarity search using extended connectivity fingerprints
(ecfp4) for compounds is performed (27). Identical com-
pounds are excluded by requiring the Tanimoto similar-
ity to be less than one. If there are suitable candidates,
their corresponding known targets are evaluated and, based
on associated indications, potential repositioning areas are
suggested.
Should the specified drug already be contained in the
database and should there be indications associated with it,
the corresponding ICD-10 codes are excluded from the pro-
posed results. Therefore, in the case of existing known indi-
cations, these are separately displayed in the result screen
for reference.
Additionally, for structures previously contained in the
database, all known targets that are associated with indi-
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targets with the reference compounds are excluded from the
main results.
Network
The network, established from either a compound or indi-
cation, interlinks compounds, side-effects, indications, and
target- as well as drug–drug interactions. Spherical mark-
ers represent side-effects (blue), indications (red), target in-
teractions (yellow) and drug–drug interactions (green). Se-
lecting a graph node shows further information and allows
additional connected nodes to be added. Not needed nodes
can be removed from the graph and additionally, each node
can be dragged to rearrange it. Scrolling over a particular
area provides zoom and it is also possible to hover over a
node to enlarge its name.
Additional search options
As an addition to the interactive functionalities of the
database, a compilation of supporting information to drugs
and targets was included. Since it is both directly searchable
and browsable by indications and ATC-codes, it provides
functionalities usable by experts and non-experts alike.
Searching for a drug or compound in Promiscuous 2.0
is based on comparing a user specified input structure to
all compound structures contained in the database via their
respective molecular fingerprints. Therefore, researchers in-
terested in a particular drug or compound are given differ-
ent options to specify their molecular structure of interest,
the simplest of which is to enter the PubChem (28) name,
which results in the corresponding molecular structure be-
ing uploaded to the integrated ChemDoodle (29) structure
viewer. Here, it is possible to preview the transmitted struc-
ture as well as make modifications, such as the deletion or
addition of single atoms or substructures. Similarly, it is
also possible to draw a molecule structure completely from
scratch using the provided drawing tools. Additionally, it
is possible to enter a SMILES string (30) describing the
molecular structure or to a file containing the molecular
structure (Figure 1E).
Upon starting the similarity search the database is
queried with the input structure and once the comparisons
are finished, all highly similar compounds are listed and
sorted according their Tanimoto coefficient, with a Tani-
moto similarity equal to 1 indicating that the structure from
the database is identical to the queried structure. Here, it is
possible to choose a molecule from the results to display
more detailed information, such as known and predicted
targets or associated indications and side effects.
To search for a specific target, there are also different
identifiers available. In addition to UniProt accession num-
bers and names, it is also possible to use gene names to iden-
tify a target or to perform a simple text search for target
names. Except for seaching for a specific UniProt accession
number, a substring search is performed which can poten-
tially produce multiple results, even though only the first 20
hits are reported to the user.
The result page contains an overview over all obtained
protein targets, including tables containing indications and
drugs if available for the specific target. From here, it is also
possible to directly select one of the associated drugs and
display the corresponding drug details.
As an option that requires minimal background knowl-
edge, a browsing functionality was newly implemented in
Promiscuous 2.0. This feature enables users to find drugs
and targets that are associated with specific diseases or work
in specific organs. For this purpose drugs were associated
with diseases via the International Classification of Diseases
10th Revision (ICD-10) as well as according to the Anatom-
ical Therapeutic Chemical Classification System (ATC). By
either scrolling through the whole list of available ICD-10
and ATC-codes or through filtering the list of options by
typing in a disease or area of interest, it is possible to se-
lect a specific code and search for drugs or targets associ-
ated with it. The obtained result screens resemble the result
pages of the direct drug and targets searches, respectively,
by displaying a list of drugs and targets with the possibility
to select a drug to gain additional information.
EXAMPLE APPLICATION
As an example drug, warfarin, one of the most widely used
anticoagulants worldwide, was chosen (31). To use the drug
repositioning option, simply entering the name ‘warfarin’ is
sufficient to load its structure and start the similarity search.
The result screen reports a total of four potential new indi-
cations for warfarin, which can be traversed via clicking on
parts of the pie charts. The larger chart corresponds to a
broader compilation of ICD-10 categories and clicking on
a single slice changes the small chart to represent the ICD-
10 subcategories corresponding to the selected slice. Upon
clicking on either of the pie charts, a table with detailed in-
formation for the chosen ICD-10 categories is displayed un-
derneath the graphic (Figure 1C).
When evaluating the results for warfarin, the newly re-
ported indications are given as thus according to their ICD-
10-codes: G20: Parkinson disease, G43: Migraine, G47:
Sleep disorders and F51: Nonorganic sleep disorders. For
each of the indications it is reported from which reference
compound(s) the indication was derived and how high the
Tanimoto similarity between the compounds was. For ex-
ample, Parkinson disease was suggested as a new applica-
tion area for warfarin due to the structural similarity to
ethyl biscoumacetate (Figure 1C).
As an alternative, it is possible to use the network vi-
sualization function to obtain new indications for existing
drugs, or vice versa to find new compounds possibly associ-
ated with a disease of interest. By starting with the ICD-10
categories G20–G26 (Figure 2A), which include Parkinson,
it is possible to find medications with a potential connec-
tion to the indications. The addition of one set of associ-
ated targets brings up GLUL (Figure 2B), which is iden-
tified as Glutamine synthetase when clicking on the corre-
sponding node. When searching for drugs and compounds
that interact with the enzyme, after two drug additions,
ethyl biscoumacetate (Figure 2C) is found. Finally, after
one addition of drugs that interact with ethyl biscoumac-
etate, warfarin is added to the network (Figure 2D). As ap-
parent from the network (Figure 2), there is no connection
from warfarin to Parkinson, but via interacting compounds
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Figure 2. Network representation of new indication for warfarin. (A) Starting with the indication G20–G26 to explore the database for possible new
drugs (1 click to add indication-target interactions); (B), GLUL appears for a common target in the treatment of e.g. Parkinson, which is part of the
input indication of A (click two times to add target-drug interactions); (C), one known drug for GLUL is ‘ethyl biscoumacetate’ (search for drug-drug-
interactions); (D) by this, warfarin becomes visible. Due to the cheminformatics behaviour of similar structures as well as the fact that drugs affect each
other share similar mechanism of actions, it could be suggested for the starting indication from A.
interactions, which suggest a similar interaction profile, is
found.
The potential treatment of Parkinson with warfarin is
supported by warfarin already having completed Phase 1
Trials for Parkinson’s disease Treatment in 2014. Similarly,
for the other suggested application areas, warfarin is fre-
quently reported to be effective in the treatment of Migraine
(32–34).
Another opportunity for drug repositioning is presented
with the addition of predicted targets to Promiscuous 2.0.
For warfarin there are three potential targets predicted (Fig-
ure 1B). Searching for these targets reveals that they are
associated with indications such as Huntington’s disease
or Osteoporosis. Likewise, there are reports showing that
warfarin can be effective against Huntington’s disease (35).
Contrarily, in the case of Osteoporosis, there are articles
showing that warfarin can negatively affect bone density
(36,37).
These reports support the validity of the results, but also
stress the importance of carefully considering the positive
or negative nature of the inferred associations.
This is additionally reinforced by the application of the
machine learning models to predict possible interactions of
warfarin. In addition to a number of heart diseases, which
are closely connected to the approved indication of war-
farin as an anticoagulant (31), two other clusters of indi-
cations are found, the first being various forms of joint dis-
order, such as arthropathies, the second various forms of
noeplasms. warfarin is hereby frequently associated with
hemarthrosis, a joint bleeding disorder which can be in-
duced by anticoagulation therapy (38,39), whereas in a 2017
population-based cohort study in 1.2 million people, it was
found that there was a significantly lower influence rate of
cancer among warfarin users compared to non-users, which
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Additionally, a machine learning model specifically
for the proposal of drugs that could be potentially ac-
tive against Covid-19 was developed. In order to obtain
such a model, 53 candidate drugs, including angiotensin-
converting enzyme 2 (the host cell receptor for the S pro-
tein of SARS-CoV-2) inhibitors, and a series of various
antiviral drugs were used as training data for a random
forest approach. Using this method, a total of 230 drugs
that could potentially limit the spread of SARS-CoV-2 or
mortality of COVID-19 were obtained. According to this,
among the highest-ranking drugs are corticosteroids, such
as budesonide, dexamethasone and betamethasone, where
the former two are already evaluated as candidate drugs
against COVID-19, whereas the latter one is not. Also in-
terestingly, estradiol is among the proposed drugs against
COVID-10, whereas testosterone as well as various testos-
terone derivatives did not make the cut, reinforcing the the-
ory that the worse clinical course in infected men could be
linked to testosterone levels (41). Also, among the suggested
drugs is loperamide, which was shown to inhibit the in vitro
replication of MERS- and SARS-CoV (42). However, lop-
eramide has a low oral absorption rate and is unable to cross
the blood-brain-barrier (43), which are both factors that
are not taken into consideration when predicting the effec-
tiveness against COVID-19. Therefore, even though the in
vitro effectiveness against related coronaviruses supports it
as a potential finding against COVID-19, this example also
shows that the given suggestions need to be carefully evalu-
ated. Since the prediction is solely based on structural fea-
tures, other deterring properties regarding (low) drug ab-
sorption or mechanism of action might exist, which are
not addressed by the machine learning methodology. These
properties need to be considered when evaluating the pre-
dictions.
DISCUSSION
Promiscuous 2.0 represents an extensive update to the pre-
viously existing Promiscuous database, both in the amount
of data and the introduction of all new features. Apart from
having new information added to it, the previous Promis-
cuous database has been expanded and advanced in almost
all areas (Table 1). The focus of the database was shifted
with regards to drug repositioning features by adding pre-
dicted targets and indications for drugs as well as targets.
Combining the information provides easily accessible and
unique features, that list potential drug repositioning op-
portunities in a comprehensible way.
Even though the amount of data was vastly increased, it
is, of course, impossible to claim absolute completeness of
the data, which can of course lead to oversights in the sug-
gested predictions. Additionally, the quality of prediction
algorithms always depends on the quality of the underlying
data, which, due to its size, is not feasible to curate manu-
ally. Therefore, the data was collected and filtered from es-
tablished databases, such as ChEMBL (16), Drugbank (15)
and TTD (25), in order to achieve a compromise between
amount and quality of the data. Still, as is always the case
for predictions, the suggestions need to be carefully evalu-
ated and interpreted, as illustrated with the potential detri-
mental role of warfarin in Osteoporosis and the problematic
absorption of loperamide.
Advantages of promiscuous
In recent years, a number of databases with a focus on drug
repositioning have emerged, though none as comprehensive
as Promiscuous 2.0 and for the most part applying different
methods and functionalities.
RepurposeDB serves as a compendium of successfully
repositioned drugs, annotated amongst others with primary
and secondary indications (17). In contrast to Promiscuous
2.0, it completely lacks interactive features like the sugges-
tion of new indications or an interactive network represen-
tation. Additionally, with only 250 compounds it contains
a very low number of drugs that are only searchable either
as a whole list or by submitting a complete input structure.
Similarly, repoDB lists drugs with annotated indications,
but contains no further information or features at all (18).
The Experimental Knowledge-Based Drug Reposition-
ing Database (19) is based on a similar principle as Promis-
cuous 2.0 and compiles drug repositioning opportunities
upon searching for specific drugs, but does so solely based
on information associated with the drug in question such
as known targets or scientific articles describing researched
repositioning areas for this drug. In addition, as no similar-
ity search or similar means are performed, the functionality
is not applicable to newly derived structures. Moreover, it
has considerably less entries than Promiscuous 2.0 (Table
1).
The Drug ReposER webserver operates on the assump-
tion that targets with structurally similar binding sites bind
to similar drugs and therefore identifies new potential tar-
gets for compound structures via molecular docking and
proposes them as protein targets for drug repositioning (44).
However, the method solely provides predicted targets and
fails to report associated indications or to take any addi-
tional criteria into account, such as structural similarity to
known drugs.
The DrugSig resource for computational drug reposi-
tioning uses the comparison of gene expression signatures
to the signature of known drugs as basis for drug reposition-
ing (20). Since a gene expression profile of up- and down-
regulated genes is required as input, its accessibility is quite
limited. Moreover, it only contains 1300 drugs, 800 targets
and 6000 gene expression signatures, which further limits its
scope.
Further directions
We will regularly update the database with new entries to
ensure excellent coverage and data quality standards. Espe-
cially, all data used for suggestions of drug repositioning op-
portunities will be further enriched. The similarity method
will also be further developed and improved in regard of va-
lidity. We also plan to improve the network representation
to serve all requirements of the users. We plan to include co-
morbidities in a future version to ensure better suggestions.
To further enhance the functionality, we plan to include
additional data from relevant databases, especially regard-
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Table 1. Comparison of data amount and availability of features in Promiscuous 2.0 to the old Promiscuous release and a selection of databases with a
focus on drug repositioning
Promiscuous 2.0 Promiscuous EK-DRD RepurposeDB repoDB
Drugs and 
compounds
991,805 25,170 1,963 253 1,571
Targets 9,430 6,548 2,985 305 0
Drug-target-
interactions

















yes no no no no
predicted targets yes no no no no
ATC mapping yes no no no no
Network 
visualization
interactive interactive static static none
the prediction algorithm and simplify the filtering and eval-
uation of the results. Additionally, a REST API will be im-
plemented to increase programmatic access to our Promis-
cuous database.
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